New COVID-19 Study Findings Recently Were Reported by Researchers at Pfizer (Budget Impact of Oral Nirmatrelvir/ritonavir In Adults At High Risk for Progression To Severe Covid-19 In the United States): Coronavirus – COVID-19

2024 MAR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Chemicals & Chemistry Business Daily -- Current study results on Coronavirus - COVID-19 have been published. According to news originating from Stockholm, Sweden, by NewsRx correspondents, research stated, “Nirmatrelvir/ritonavir (NMV/r) is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19. NMV/r has also been authorized for emergency use by the US Food and Drug Administration for the treatment of mild-to-moderate COVID-19 in pediatric patients (aged >= 12 years and weighing at least 40 kg) who are at high risk for progression to severe COVID-19.”

Our news journalists obtained a quote from the research from Pfizer, “Understanding the budget impact of introducing NMV/r for the treatment of adults with COVID-19 is of key interest to US payers. To estimate the annual budget impact of introducing NMV/r in a US commercial health plan setting in the current Omicron COVID-19 era. A budget impact model was developed to assess the impact of NMV/r on health care costs in a hypothetical 1-millionmember commercial health insurance plan over a 1-year period in the US population; clinical and cost inputs were derived from published literature with a focus on studies in the recent COVID-19 era that included vaccinated population and predominance of the Omicron variant. In the base-case analysis, it was assumed the only effect of NMV/r was a reduction in incidence (not severity) of hospitalization or death; its potential effect on post-COVID conditions was assessed in a scenario analysis. Outcomes included the number of hospitalizations, total cost, per patient per year (PPPY) costs, and per member per month (PMPM) costs. Sensitivity and scenario analyses were conducted to assess uncertainty around key model inputs. An estimated 29,999 adults were eligible and sought treatment with oral antiviral for COVID-19 over 1 year. The availability of NMV/r was estimated to reduce the number of hospitalizations by 647 with a total budget impact of $2,733,745, $91 PPPY, and $0.23 PMPM. NMV/r was cost saving when including post-COVID conditions with a -$1,510,780 total budget impact, a PPPY cost of -$50, and a PMPM cost of -$0.13. Sensitivity analyses indicated results were most sensitive to the risk of hospitalization under supportive care, risk of hospitalization with NMV/r treatment and cost of NMV/r.”

According to the news editors, the research concluded: “Treatment with NMV/r in the current COVID-19 era is estimated to result in substantial cost offsets because of reductions in hospitalization and modest budget impact to potential overall cost savings.”

This research has been peer-reviewed.

For more information on this research see: Budget Impact of Oral Nirmatrelvir/ritonavir In Adults At High Risk for Progression To Severe Covid-19 In the United States. Journal of Managed Care & Specialty Pharmacy, 2023;29(12):1290-1302. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

The news correspondents report that additional information may be obtained from Rickard Sandin, Pfizer, Stockholm, Sweden. Additional authors for this research include David L. Veenstra, Sean D. Sullivan, David Campbell, Mathilde Vankelegom, Cuiying Ma, Cale Harrison, Mendwas Dzingina, Tendai Mugwagwa, Florin Draica and Timothy Lee Wiemken.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.18553/jmcp.2023.29.12.1290. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)